Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease, with lupus nephritis (LN) affecting up to 60% of patients. Early diagnosis and treatment are critical for preserving kidney function. In a Review recently published in AJKD, the authors discuss current and emerging therapies for proliferative and membranous LN with a focus on strategies targeting underlying mechanisms of disease in LN.
Schematic diagram of immunopathogenic pathways in lupus nephritis and site of action of therapies targeting them. Figure 2 from Desai et al, © National Kidney Foundation.
AJKDBlog’s Interviews Editor, Timothy Yau chatted with authors Niraj B. Desai, Casey Gashti, and about the history of LN and several exciting new therapies.
If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Drs. Desai, Gashti, and for their time and insight!
To view this Original Investigation by Desai et al [free], please visit AJKD.org:
Title: “A Change Is Gonna Come” to Treatment of Lupus Nephritis: A Review
Authors: Niraj B. Desai, Casey Gashti, and William L. Whittier
DOI: 10.1053/j.ajkd.2025.08.016